Health Care legislation moves to Conference
The House and Senate agree on the need to strengthen primary care, but prescription-drug provisions added by the House now form part of the conference discussion.
Massachusetts ended formal legislative sessions with one of the session’s major health care bills still unresolved.
The Senate passed its primary care bill in June. The House approved a substantially different version on July 30, and the two branches appointed a conference committee the following day after the Senate declined to accept the House changes. Negotiators will now work to determine whether the branches can reach a final agreement.
Both the House and Senate agree on the need to strengthen primary care, address workforce shortages, and improve access. But the House version also brought broader prescription-drug policy into the discussion.
These ideas may sound straightforward, but their effects are more complicated.
Neither provision requires pharmaceutical manufacturers to lower the price of a drug or creates new savings within the health care system. Instead, they change how existing rebates and financial assistance are applied.
While that may reduce pharmacy-counter costs for some patients, it may also leave fewer dollars available to lower premiums for the rest. Manufacturer assistance can provide important short-term help, but it can also make very expensive brand-name drugs more affordable to use without requiring the manufacturer to reduce the drug’s underlying price. They certainly don’t lower the list price set by drug manufacturers.
When the costs are borne by union and business health plans, workers and families, those tradeoffs deserve scrutiny and review.
A New Transparency System Is Just Beginning Its Work
The current debate is unfolding shortly after Massachusetts enacted a major pharmaceutical access, cost, and transparency law.
Chapter 342 of the Acts of 2024 established a new PBM licensing system, expanded oversight of pharmaceutical manufacturers and PBMs, and required detailed reporting to the Center for Health Information and Analysis. The law was intended to give Massachusetts a clearer view of drug prices, rebates, fees, pharmacy reimbursement, and how prescription-drug dollars move through the system.
That framework is still being implemented.
PBMs were required to obtain Massachusetts licenses beginning January 1, 2026. CHIA’s first PBM reporting cycle, due June 1, includes information on rebates, administrative fees, formularies, maximum allowable cost lists, spread pricing, and pharmacy clawbacks. CHIA has described this as the first reporting cycle and expects to evaluate and refine the process based on what the initial submissions show.
That work gives Massachusetts an opportunity to move beyond assumptions and truly evaluate how the pharmaceutical market is operating and what policy changes should be made.
It would be premature to draw final conclusions before the state agencies charged with collecting this information have had a meaningful opportunity to analyze it.
Affordability Requires Looking at the Whole System
Massachusetts’ health care affordability challenge does not begin or end with any one participant.
Pharmaceutical manufacturers establish drug launch prices and decide when to increase them. Hospitals and health systems account for a significant portion of health care spending. Employers and union health funds are trying to maintain meaningful coverage as costs continue to rise. PBMs, insurers, pharmacies and providers all operate within that broader system.
Good policy should distinguish between reforms that lower total costs and policies that merely move costs from one place to another, as is the case with the House’s reform of “point-of-sale” rebates.
It should also recognize that strengthening primary care is an important objective in its own right. A primary care bill should not become a vehicle for unrelated prescription-drug mandates without a clear understanding of their consequences.
An Opportunity for a Deliberate Approach
The conference committee now has an opportunity to produce a thoughtful primary care bill while taking a measured approach to the additional policies before it.
That means examining whether proposed prescription-drug provisions will deliver genuine savings, considering their impact on businesses and union health funds, and allowing the Commonwealth’s new transparency framework to inform future decisions.
Massachusetts has already asked PBMs for considerably more information. The first round of that information is only now being collected and evaluated.
The next step should be to use it.
A final agreement should strengthen primary care, protect access, and advance affordability. It should not simply shift costs among patients, workers, employers, and health plans to appease interests with deep pockets.